SEARCH:   Advanced

Blood, 15 December 2007, Vol. 110, No. 13, pp. 4584-4587. Prepublished online as a Blood First Edition Paper on September 7, 2007; DOI 10.1182/blood-2007-07-101071. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-07-101071v1 110/13/4584    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Frangoul, H. Articles by Grupp, S. A. Search for Related Content PubMed PubMed Citation Articles by Frangoul, H. Articles by Grupp, S. A. Related Collections Transplantation Chemokines, Cytokines, and Interleukins Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION A prospective study of G-CSF–primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium (PBMTC) study Haydar Frangoul1, Eneida R. Nemecek2, Dean Billheimer3, Michael A. Pulsipher4, Shakila Khan5, Ann Woolfrey6, Becky Manes1, Catherine Cole7, Mark C. Walters8, Mouhab Ayas9, Yaddanapudi Ravindranath10, John E. Levine11, and Stephan A. Grupp12 1 Department of Pediatrics, Vanderbilt University, Nashville, TN; 2 Department of Pediatrics, Oregon Health & Science University, Portland, OR; 3 Department of Biostatistics, Vanderbilt University, Nashville, TN; 4 Department of Pediatrics, Primary Children's Medical Center, University of Utah, Salt Lake City, UT; 5 Department of Pediatrics, Mayo Clinic, Rochester, MN; 6 Department of Pediatrics, Fred Hutchinson Cancer Center, Seattle, WA; 7 Department of Pediatrics, Princess Margaret Hospital for Children, Perth, Australia; 8 Department of Pediatrics, Children's Hospital Oakland & Research Center, Oakland, CA; 9 Department of Pediatrics, King Faisal Medical Center, Riyadh, Saudi Arabia; 10 Department of Pediatrics, Wayne State University, Detroit, MI; 11 Department of Pediatrics, University of Michigan, Ann Arbor, MI; and 12 Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA A prospective multicenter trial was conducted to evaluate the safety and feasibility of granulocyte colony-stimulating factor (G-CSF)–primed bone marrow (G-BM) in children receiving allogeneic bone marrow transplantation (BMT). A total of 42 children with a median age of 9.8 years (range, 0.8-17 years) were enrolled. Donors with median age of 9.2 years (range, 1.1-22 years) received 5 µg/kg per day of subcutaneous G-CSF for 5 consecutive days. BM was harvested on the fifth day. No donor experienced complications related to G-CSF administration or marrow har-vest. Median nucleated (NC) and CD34 cells infused was 6.7 x 108/kg (range, 2.4-18.5 x 108/kg) and 7.4 x 106/kg (range, 2-27.6 x 106/kg), respectively. Neutrophil and platelet engraftment was at a median of 19 days (range, 13-28 days) and 20 days (range, 9-44 days), respectively. A total of 13 (32%) patients developed grade 2 graft-versus-host disease (GVHD), and 5 (13%) of 40 evaluable patients developed chronic GVHD (3 limited and 2 extensive). Higher cell dose was not associated with increased risk of acute or chronic GVHD. Overall survival and event-free survival at 2 years were 81% and 69%, respectively. Collection of G-BM from pediatric donors is safe, and can result in high NC and CD34 cell doses that facilitate engraftment after myeloablative BMT without a discernable increase in the risk of GVHD. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020